13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001535610
Total reported value
$110.5M
$110.5M
28 檔
4.6%
During the Q1 2026 filing period, Sabby Management, LLC (CIK: 0001535610) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $110.5M across 28 reported positions.
In Q1 2026, Sabby Management, LLC adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 19 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 19.92% | -16.20% | +716.12% | |
| 2 | ✓ | Gevo Inc | Stock-Other | 16.06% | -16.06% | EXIT | |
| 3 | ✓ | Abivax SA | Stock-Other | 9.60% | -8.61% | -51.88% | |
| 4 | ✓ | Stock-Other | 7.33% | -7.33% | EXIT | ||
| 5 | BCTXL | Briacell Therapeutics CORP | Stock-Other | 4.39% | -4.24% | — | |
| 6 | SNES | Senestech Inc | Stock-Other | 4.01% | -3.82% | +3.78% | |
| 7 | ✓ | Big Tree Cloud Hldgs LTD | Stock-Other | 3.78% | -3.78% | EXIT | |
| 8 | ✓ | Zevra Therapeutics Inc | Stock-Other | 3.55% | -3.00% | +3.98% | |
| 9 | BCTX | Briacell Therapeutics CORP | Stock-Other | 3.47% | -3.23% | — | |
| 10 | ✓ | Spdr S&P 500 Etf Tr Put Option | ETF-Large Cap & Growth | 3.26% | +45.73% | +28.08% | |
| 11 | ✓ | Sidus Space Inc | Stock-Other | 2.73% | -1.99% | — | |
| 12 | TC | Token Cat LTD | Stock-Other | 2.71% | -2.71% | EXIT | |
| 13 | ✓ | Pop Culture Group Co LTD | Stock-Other | 2.25% | -2.25% | EXIT | |
| 14 | MBRX | Moleculin Biotech Inc | Stock-Other | 1.92% | -1.92% | EXIT | |
| 15 | ✓ | Stock-Other | 1.78% | -1.78% | EXIT | ||
| 16 | RKDA | Arcadia Biosciences Inc | Stock-Other | 1.77% | -1.77% | EXIT | |
| 17 | TRX | Trx Gold CORP | Stock-Other | 1.68% | -1.68% | EXIT | |
| 18 | INM | Inmed Pharmaceuticals Inc | Stock-Other | 1.59% | -1.53% | +9.24% | |
| 19 | CANF | Can Fite Biopharma Ltd-adr | Stock-Other | 1.48% | -1.48% | EXIT | |
| 20 | ✓ | China Sxt Pharmaceuticals In | Stock-Other | 1.47% | -1.47% | EXIT | |
| 21 | REVB | Revelation Biosciences Inc | Stock-Other | 1.34% | -1.14% | — | |
| 22 | CLDI | Calidi Biotherapeutics Inc | Stock-Other | 1.16% | -1.16% | EXIT | |
| 23 | ✓ | Ishares Tr | Stock-Other | 0.83% | +11.16% | -53.85% | |
| 24 | BJDX | Bluejay Diagnostics Inc | Stock-Other | 0.59% | -0.59% | EXIT | |
| 25 | LYRA | Lyra Therapeutics Inc | Stock-Other | 0.57% | -0.57% | EXIT | |
| 26 | TPST | Tempest Therapeutics Inc | Stock-Other | 0.33% | +0.18% | -90.00% | |
| 27 | BCTXZ | Briacell Therapeutics - 30 | Stock-Other | 0.32% | -0.31% | -22.26% | |
| 28 | BNBX | Bnb Plus CORP | Stock-Other | 0.10% | -0.10% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | +18.5% | +716.12% | Add |
| 2 | ✓ | Gevo Inc | +8.4% | -16.29% | Trim |
| 3 | ✓ | +7.3% | NEW | New buy | |
| 4 | BCTXL | Briacell Therapeutics CORP | +4.4% | NEW | New buy |
| 5 | ✓ | Big Tree Cloud Hldgs LTD | +3.8% | NEW | New buy |
| 6 | BCTX | Briacell Therapeutics CORP | +3.5% | NEW | New buy |
| 7 | ✓ | Sidus Space Inc | +2.7% | NEW | New buy |
| 8 | TC | Token Cat LTD | +2.7% | NEW | New buy |
| 9 | MBRX | Moleculin Biotech Inc | +1.9% | NEW | New buy |
| 10 | ✓ | Spdr S&P 500 Etf Tr Put Option | +1.8% | +28.08% | Add |
| 11 | RKDA | Arcadia Biosciences Inc | +1.8% | NEW | New buy |
| 12 | ✓ | Zevra Therapeutics Inc | +1.8% | +3.98% | Add |
| 13 | TRX | Trx Gold CORP | +1.7% | NEW | New buy |
| 14 | CANF | Can Fite Biopharma Ltd-adr | +1.5% | NEW | New buy |
| 15 | ✓ | China Sxt Pharmaceuticals In | +1.5% | NEW | New buy |
| 16 | REVB | Revelation Biosciences Inc | +1.3% | NEW | New buy |
| 17 | SNES | Senestech Inc | +1.3% | +3.78% | Add |
| 18 | CLDI | Calidi Biotherapeutics Inc | +1.2% | NEW | New buy |
| 19 | BJDX | Bluejay Diagnostics Inc | +0.6% | NEW | New buy |
| 20 | INM | Inmed Pharmaceuticals Inc | +0.3% | +9.24% | Add |
| 21 | ✓ | Eos Energy Enterprises Inc | 0% | EXIT | Sold out |
| 22 | LMFA | Lm Funding America Inc | -0.1% | EXIT | Sold out |
| 23 | ✓ | Ishares Tr | -0.2% | -53.85% | Trim |
| 24 | BCTXZ | Briacell Therapeutics - 30 | -0.2% | -22.26% | Trim |
| 25 | ✓ | Pop Culture Group Co LTD | -0.2% | -30.54% | Trim |
| 26 | OGEN | Oragenics Inc | -0.3% | EXIT | Sold out |
| 27 | BNBX | Bnb Plus CORP | -0.3% | -74.92% | Trim |
| 28 | PMCB | Pharmacyte Biotech Inc | -0.4% | EXIT | Sold out |
| 29 | ✓ | Reviva Pharmaceutcls Hldgs Inc | -0.7% | EXIT | Sold out |
| 30 | ✓ | Ishares Tr | -0.9% | EXIT | Sold out |
| 31 | ✓ | -0.9% | +35.04% | Add | |
| 32 | ✓ | Epicquest Educatn Grp Intl L | -0.9% | EXIT | Sold out |
| 33 | NUWE | Nuwellis Inc | -1% | EXIT | Sold out |
| 34 | QM30 | Nova Minerals Ltd-adr | -1.1% | EXIT | Sold out |
| 35 | ✓ | Tian Ruixiang Hldgs LTD | -1.4% | EXIT | Sold out |
| 36 | ✓ | Globavend Holdings LTD | -1.6% | EXIT | Sold out |
| 37 | ✓ | Jiuzi Holdings Inc | -2% | EXIT | Sold out |
| 38 | ZONE | Cleancore Solutions Inc-cl B | -2.3% | EXIT | Sold out |
| 39 | LYRA | Lyra Therapeutics Inc | -2.7% | -40.59% | Trim |
| 40 | TPST | Tempest Therapeutics Inc | -2.8% | -90.00% | Trim |
| 41 | ✓ | -3% | EXIT | Sold out | |
| 42 | ✓ | Abivax SA | -3.6% | -51.88% | Trim |
| 43 | ABVX | Abivax Sa-adr | -5.8% | EXIT | Sold out |
| 44 | ✓ | Bitcoin Depot Inc | -7.9% | EXIT | Sold out |
| 45 | BLNK | Blink Charging Co | -8.7% | EXIT | Sold out |
| 46 | EMPD | Empery Digital Inc | -9.5% | EXIT | Sold out |
| 47 | ✓ | -9.6% | EXIT | Sold out |
According to official SEC Form 13F filings, Sabby Management, LLC reported a total U.S. public equity portfolio value of $110.5M across 28 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, GEVO INC, ABIVAX SA) accounted for 4.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
市值: $654.8K
Top Position Liquidated / Trimmed
前期市值: $1.6M
During Q1 2026, Sabby Management, LLC's top holdings by market value included SPY (19.9%)、GEVO INC (16.1%)、ABIVAX SA (9.6%). The largest single position, SPY, represented 19.9% of total portfolio value.
In Q1 2026, Sabby Management, LLC made 47 total portfolio adjustments, initiating 14 new buys, adding to 6 positions, trimming 8 holdings, and fully liquidating 19 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.